{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:18:57Z","timestamp":1793755137546,"version":"4.6.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Morton Plant Mease Health Care Foundation"},{"name":"NIH\/NIA","award":["R01AG079241"],"award-info":[{"award-number":["R01AG079241"]}]},{"name":"NIH\/NIA","award":["R21AG079794"],"award-info":[{"award-number":["R21AG079794"]}]},{"DOI":"10.13039\/100002558","name":"Warren Alpert Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01668-5","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:06:07Z","timestamp":1736499967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Swetha","family":"Ravichandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Alber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Murchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Chaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1668_CR1","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u20131695.","DOI":"10.1002\/alz.13016"},{"issue":"14","key":"1668_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1001\/jama.2018.0158","volume":"319","author":"AH Mokdad","year":"2018","unstructured":"US Burden of Disease Collaborators, Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, Mullany E, Lee A, et al. The state of US Health, 1990\u20132016: Burden of diseases, injuries, and risk factors among US States. JAMA. 2018;319(14):1444\u201372.","journal-title":"JAMA"},{"issue":"2","key":"1668_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2190\/DV3R-PBJQ-E0FT-7W2B","volume":"25","author":"A La Rue","year":"1987","unstructured":"La Rue A, Jarvik LF. Cognitive function and prediction of dementia in old age. Int J Aging Hum Dev. 1987;25(2):79\u201389.","journal-title":"Int J Aging Hum Dev"},{"key":"1668_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1001\/archneur.1995.00540290075020","volume":"52","author":"RT Linn","year":"1995","unstructured":"Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, et al. The\u2019preclinical phase\u2019of probable Alzheimer\u2019s disease: a 13-year prospective study of the Framingham cohort. Arch Neurol. 1995;52:485\u201390.","journal-title":"Arch Neurol"},{"key":"1668_CR5","doi-asserted-by":"crossref","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351\u20137.","DOI":"10.1016\/S0197-4580(97)00056-0"},{"issue":"7","key":"1668_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.1996.03530310034029","volume":"275","author":"DA Snowdon","year":"1996","unstructured":"Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer\u2019s disease in late life. Findings from the Nun Study. JAMA. 1996;275(7):528\u201332.","journal-title":"JAMA"},{"issue":"6","key":"1668_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archneur.57.6.808","volume":"57","author":"MF Elias","year":"2000","unstructured":"Elias MF, Beiser A, Wolf PA, Au R, White RF, D\u2019Agostino RB. The preclinical phase of alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57(6):808\u201313.","journal-title":"Arch Neurol"},{"issue":"3","key":"1668_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17(3):241\u201350.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1668_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1668_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1668_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"key":"1668_CR12","doi-asserted-by":"crossref","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386.","DOI":"10.1038\/s41591-020-0755-1"},{"issue":"3","key":"1668_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"key":"1668_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, P\u00e9rez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid \u03b2 42\/40 ratios as biomarkers for amyloid \u03b2 cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179\u201387.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1668_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","volume":"650","author":"W Zhou","year":"2017","unstructured":"Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neurosci Lett. 2017;650:60\u20134.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1668_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neulet.2007.02.090","volume":"420","author":"C Paquet","year":"2007","unstructured":"Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer\u2019s disease. Neurosci Lett. 2007;420(2):97\u20139.","journal-title":"Neurosci Lett"},{"issue":"7","key":"1668_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.clineuro.2011.02.014","volume":"113","author":"A Kesler","year":"2011","unstructured":"Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer\u2019s disease. Clin Neurol Neurosurg. 2011;113(7):523\u20136.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"1668_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-023-01312-8","volume":"15","author":"E Arthur","year":"2023","unstructured":"Arthur E, Ravichandran S, Snyder PJ, Alber J, Strenger J, Bittner AK, et al. Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimer\u2019s disease. Alzheimers Res Ther. 2023;15(1):172.","journal-title":"Alzheimers Res Ther"},{"key":"1668_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3389\/fphys.2018.01721","volume":"9","author":"D Cabrera DeBuc","year":"2018","unstructured":"Cabrera DeBuc D, Somfai GM, Arthur E, Kostic M, Oropesa S, Mendoza Santiesteban C. Investigating Multimodal Diagnostic Eye biomarkers of cognitive impairment by measuring vascular and neurogenic changes in the Retina. Front Physiol. 2018;9:1721.","journal-title":"Front Physiol"},{"issue":"4","key":"1668_CR20","doi-asserted-by":"publisher","first-page":"041109","DOI":"10.1117\/1.NPh.6.4.041109","volume":"6","author":"E Arthur","year":"2019","unstructured":"Arthur E, Somfai GM, Kostic M, Oropesa S, Santiesteban CM, DeBuc DC. Distinguishing cognitive impairment by using singularity spectrum and lacunarity analysis of the retinal vascular network. Neurophotonics. 2019;6(4):041109.","journal-title":"Neurophotonics"},{"issue":"16","key":"1668_CR21","doi-asserted-by":"publisher","first-page":"e93621","DOI":"10.1172\/jci.insight.93621","volume":"2","author":"Y Koronyo","year":"2017","unstructured":"Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight. 2017;2(16):e93621.","journal-title":"JCI Insight"},{"issue":"1","key":"1668_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40478-018-0650-x","volume":"6","author":"J den Haan","year":"2018","unstructured":"den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer\u2019s disease retinas. Acta Neuropathol Commun. 2018;6(1):147.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"1668_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.65.5.5","volume":"65","author":"S Ravichandran","year":"2024","unstructured":"Ravichandran S, Snyder PJ, Alber J, Kenny MR, Rothstein A, Brown K, et al. Quantifying putative retinal gliosis in preclinical Alzheimer\u2019s Disease. Invest Ophthalmol Vis Sci. 2024;65(5):5.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1668_CR24","first-page":"e12119","volume":"12","author":"J Alber","year":"2020","unstructured":"Alber J, Arthur E, Sinoff S, DeBuc DC, Chew EY, Douquette L, et al. A recommended minimum data set framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer\u2019s study (ARIAS). Alzheimers Dement (Amst). 2020;12(1):e12119.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"6","key":"1668_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF00175988","volume":"232","author":"AG Bennett","year":"1994","unstructured":"Bennett AG, Rudnicka AR, Edgar DF. Improvements on Littmann\u2019s method of determining the size of retinal features by fundus photography. Graefes Arch Clin Exp Ophthalmol. 1994;232(6):361\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1668_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/070674370705200508","volume":"52","author":"T Smith","year":"2007","unstructured":"Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007;52(5):329\u201332.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"1668_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"1668_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/arclin\/act057","volume":"28","author":"S Karantzoulis","year":"2013","unstructured":"Karantzoulis S, Novitski J, Gold M, Randolph C. The repeatable battery for the Assessment of Neuropsychological Status (RBANS): utility in detection and characterization of mild cognitive impairment due to Alzheimer\u2019s disease. Arch Clin Neuropsychol. 2013;28(8):837\u201344.","journal-title":"Arch Clin Neuropsychol"},{"issue":"3","key":"1668_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"1668_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.dadm.2016.09.001","volume":"4","author":"PJ Snyder","year":"2016","unstructured":"Snyder PJ, Johnson LN, Lim YY, Santos CY, Alber J, Maruff P, et al. Nonvascular retinal imaging markers of preclinical Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2016;4:169\u201378.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"1668_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/tvst.8.5.6","volume":"8","author":"BM Wong","year":"2019","unstructured":"Wong BM, Cheng RW, Mandelcorn ED, et al. Validation of optical coherence tomography retinal segmentation in neurodegenerative disease. Transl Vis Sci Technol. 2019;8(5):6\u20136.","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"1668_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","volume":"98","author":"Grading diabetic retinopathy","year":"1991","unstructured":"Grading diabetic retinopathy. From stereoscopic color fundus photographs\u2013an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5):786\u2013806.","journal-title":"Ophthalmology"},{"issue":"13","key":"1668_CR33","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1668_CR34","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/oxfordjournals.jbchem.a135662","volume":"99","author":"Y Ihara","year":"1986","unstructured":"Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer\u2019s disease. J Biochem. 1986;99(6):1807\u201310.","journal-title":"J Biochem"},{"issue":"6","key":"1668_CR35","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"1","key":"1668_CR36","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14(1):e14408.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1668_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1668_CR38","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, et al. ALFA Study. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med. 2020;12(12):e12921.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"1668_CR39","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, Langhough R, Du L, Chin NA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 2023;5(2):fcad057.","journal-title":"Brain Commun"},{"issue":"11","key":"1668_CR40","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143(11):3234\u201341.","journal-title":"Brain"},{"issue":"2","key":"1668_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188\u201399.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1668_CR42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0896-6273(95)90232-5","volume":"14","author":"J Busciglio","year":"1995","unstructured":"Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14(4):879\u201388.","journal-title":"Neuron"},{"issue":"3","key":"1668_CR43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1006\/mcne.1997.0615","volume":"9","author":"A Ferreira","year":"1997","unstructured":"Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci. 1997;9(3):220\u201334.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"1668_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0306-4522(02)00404-9","volume":"115","author":"WH Zheng","year":"2002","unstructured":"Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115(1):201\u201311.","journal-title":"Neuroscience"},{"issue":"9","key":"1668_CR45","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","volume":"29","author":"FG De Felice","year":"2008","unstructured":"De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer\u2019s disease-type neuronal tau hyperphosphorylation induced by a beta oligomers. Neurobiol Aging. 2008;29(9):1334\u201347.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"1668_CR46","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1038\/cddis.2011.50","volume":"2","author":"CJ Garwood","year":"2011","unstructured":"Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of A\u03b2-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2011;2(6):e167.","journal-title":"Cell Death Dis"},{"key":"1668_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1196\/annals.1332.006","volume":"1035","author":"M Kitazawa","year":"2004","unstructured":"Kitazawa M, Yamasaki TR, LaFerla FM. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci. 2004;1035:85\u2013103.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1668_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","volume":"129","author":"RM Nisbet","year":"2015","unstructured":"Nisbet RM, Polanco JC, Ittner LM, G\u00f6tz J. Tau aggregation and its interplay with amyloid-\u03b2. Acta Neuropathol. 2015;129(2):207\u201320.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1668_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma Phospho-Tau217 levels with tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021;78(2):149\u201356.","journal-title":"JAMA Neurol"},{"issue":"16","key":"1668_CR50","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6(16):eaaz2387.","journal-title":"Sci Adv"},{"issue":"5441","key":"1668_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.286.5441.916","volume":"286","author":"C Haass","year":"1999","unstructured":"Haass C, De Strooper B. The presenilins in Alzheimer\u2019s disease\u2013proteolysis holds the key. Science. 1999;286(5441):916\u20139.","journal-title":"Science"},{"issue":"26","key":"1668_CR52","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.1523\/JNEUROSCI.23-26-08844.2003","volume":"23","author":"JR Cirrito","year":"2003","unstructured":"Cirrito JR, May PC, O\u2019Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23(26):8844\u201353.","journal-title":"J Neurosci"},{"key":"1668_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fnagi.2018.00138","volume":"10","author":"S Lehmann","year":"2018","unstructured":"Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, et al. Relevance of A\u03b242\/40 ratio for detection of Alzheimer Disease Pathology in Clinical Routine: the PLMR Scale. Front Aging Neurosci. 2018;10:138.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"1668_CR54","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","volume":"98","author":"Y Li","year":"2022","unstructured":"Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, et al. Validation of plasma Amyloid-\u03b2 42\/40 for detecting Alzheimer Disease amyloid plaques. Neurology. 2022;98(7):e688\u201399.","journal-title":"Neurology"},{"issue":"15","key":"1668_CR55","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","volume":"94","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, P\u00e9rez-Grijalba V, Fandos N, Fowler C, Villemagne VL, Masters CL, AIBL Research Group, et al. Total A\u03b242\/A\u03b240 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology. 2020;94(15):e1580\u201391.","journal-title":"Neurology"},{"key":"1668_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fnagi.2020.00272","volume":"12","author":"C Bjorkli","year":"2020","unstructured":"Bjorkli C, Sandvig A, Sandvig I. Bridging the gap between fluid biomarkers for Alzheimer\u2019s Disease, Model systems, and patients. Front Aging Neurosci. 2020;12:272.","journal-title":"Front Aging Neurosci"},{"key":"1668_CR57","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2018;4:575\u201390.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"1668_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719\u201332.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1668_CR59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1083\/jcb.74.1.241","volume":"74","author":"WW Schlaepfer","year":"1977","unstructured":"Schlaepfer WW, Lynch RG. Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J Cell Biol. 1977;74(1):241\u201350.","journal-title":"J Cell Biol"},{"issue":"5","key":"1668_CR60","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer Disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol"},{"issue":"7","key":"1668_CR61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between Longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer Disease. JAMA Neurol. 2019;76(7):791\u20139.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1668_CR62","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316.","journal-title":"Brain"},{"issue":"1","key":"1668_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11(1):27.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"1668_CR64","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jnc.15565","volume":"164","author":"A Kumar","year":"2023","unstructured":"Kumar A, Fontana IC, Nordberg A. Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer\u2019s disease. J Neurochem. 2023;164(3):309\u201324.","journal-title":"J Neurochem"},{"issue":"1","key":"1668_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/opo.12425","volume":"38","author":"BS Ashimatey","year":"2018","unstructured":"Ashimatey BS, King BJ, Swanson WH. Retinal putative glial alterations: implication for glaucoma care. Ophthalmic Physiol Opt. 2018;38(1):56\u201365.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"2","key":"1668_CR66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/IJG.0b013e31802d045a","volume":"16","author":"MC Grieshaber","year":"2007","unstructured":"Grieshaber MC, Orgul S, Schoetzau A, Flammer J. Relationship between retinal glial cell activation in glaucoma and vascular dysregulation. J Glaucoma. 2007;16(2):215\u20139.","journal-title":"J Glaucoma"},{"issue":"4","key":"1668_CR67","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0031-1281857","volume":"229","author":"MC Grieshaber","year":"2012","unstructured":"Grieshaber MC, Moramarco F, Schoetzau A, Flammer J, Orguel S. Detection of retinal glial cell activation in glaucoma by time domain optical coherence tomography. Klin Monbl Augenheilkd. 2012;229(4):314\u20138.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"6","key":"1668_CR68","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/opo.12731","volume":"40","author":"H Cheung","year":"2020","unstructured":"Cheung H, King BJ, Gast TJ. Presumed activated retinal astrocytes and M\u00fcller cells in healthy and glaucomatous eyes detected by spectral domain optical coherence tomography. Ophthalmic Physiol Opt. 2020;40(6):738\u201351.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"10","key":"1668_CR69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.10.2","volume":"62","author":"JX Ong","year":"2021","unstructured":"Ong JX, Nesper PL, Fawzi AA, Wang JM, Lavine JA. Macrophage-like cell density is increased in proliferative Diabetic Retinopathy characterized by Optical Coherence Tomography Angiography. Invest Ophthalmol Vis Sci. 2021;62(10):2.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1668_CR70","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/diagnostics12112793","volume":"12","author":"NT Zhang","year":"2022","unstructured":"Zhang NT, Nesper PL, Ong JX, Wang JM, Fawzi AA, Lavine JA. Macrophage-like cells are increased in patients with vision-threatening Diabetic Retinopathy and correlate with Macular Edema. Diagnostics (Basel). 2022;12(11):2793.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"1668_CR71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12886-023-02794-8","volume":"23","author":"W Wang","year":"2023","unstructured":"Wang W, Sun G, Xu A, Chen C. Proliferative diabetic retinopathy and diabetic macular edema are two factors that increase macrophage-like cell density characterized by en face optical coherence tomography. BMC Ophthalmol. 2023;23(1):46.","journal-title":"BMC Ophthalmol"},{"key":"1668_CR72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ajo.2021.03.014","volume":"229","author":"C Grondin","year":"2021","unstructured":"Grondin C, Au A, Wang D, et al. Identification and characterization of Epivascular Glia using En face Optical Coherence Tomography. Am J Ophthalmol. 2021;229:108\u201319.","journal-title":"Am J Ophthalmol"},{"key":"1668_CR73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/alzrt164","volume":"5","author":"D Galasko","year":"2013","unstructured":"Galasko D, Golde TE. Biomarkers for Alzheimer\u2019s disease in plasma, serum and blood-conceptual and practical problems. Alzheimers Res Ther. 2013;5:10.","journal-title":"Alzheimers Res Ther"},{"key":"1668_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher AE, Esh CL, Kokjohn TA, Casta\u00f1o EM, Van Vickle GD, Kalback WM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease. Alzheimers Dement. 2009;5:18\u201329.","journal-title":"Alzheimers Dement"},{"key":"1668_CR75","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639\u201352.","journal-title":"Nat Rev Neurol"},{"key":"1668_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol Brain. 2019;12:1\u20137.","journal-title":"Mol Brain"},{"key":"1668_CR77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","volume":"319","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H. Blood-based biomarkers for Alzheimer\u2019s disease\u2014An update. J Neurosci Methods. 2019;319:2\u20136.","journal-title":"J Neurosci Methods"},{"key":"1668_CR78","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78:1108\u201317.","journal-title":"JAMA Neurol"},{"key":"1668_CR79","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01668-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01668-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01668-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:59:29Z","timestamp":1736503169000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01668-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01668-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the tenets of the Declaration of Helsinki, and informed consent from all subjects was obtained prior to experimental data collection after explanation of the nature and possible consequences of the study. The study was part of the Atlas of Retinal Imaging in Alzheimer\u2019s Study (ARIAS; PJS served as principal investigator for ARIAS) which took place at the University of Rhode Island and Butler Hospital Memory and Aging Program, Providence, RI between 2020 and 2022, and was approved by the BayCare Institutional Review Board (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}